NutriBand Inc. Segments Disclosure
| 10. | SEGMENT REPORTING |
We organize and manage our business by the following segments which meet the definition of reportable segments under ASC 280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the customer type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief operating decision maker (“CODM”), who is our , in making resource allocation decisions for our segments. Our CODM evaluates segment performance to the GAAP measure of gross profit.
| Years Ending | ||||||||
| January 31, | ||||||||
| 2026 | 2025 | |||||||
| Net Sales | ||||||||
| Pocono Pharmaceuticals | $ | 2,036,651 | $ | 2,139,537 | ||||
| 4P Therapeutics | ||||||||
| 2,036,651 | 2,139,537 | |||||||
| Gross Profit | ||||||||
| Pocono Pharmaceuticals | 566,308 | 743,317 | ||||||
| 4P Therapeutics | ||||||||
| 566,308 | 743,317 | |||||||
| Operating Expense | ||||||||
| Selling, general and administrative - Pocono Pharmaceuticals | 594,676 | 661,805 | ||||||
| Selling, general and administrative - 4P Therapeutics | 218,003 | 136,294 | ||||||
| Selling, general and administrative - Corporate | 6,180,461 | 3,515,711 | ||||||
| Goodwill and intangibles impairment | 3,595,216 | |||||||
| Research and development - 4P Therapeutics | 1,891,129 | 3,119,134 | ||||||
| 8,884,269 | 11,028,160 | |||||||
| Depreciation and Amortization | ||||||||
| Pocono Pharmaceuticals | $ | 156,727 | $ | 235,941 | ||||
| Corporate | 12,043 | |||||||
| 4P Therapeutics | 37,070 | 37,070 | ||||||
| $ | 193,797 | $ | 285,054 | |||||
The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.
| Years Ending | ||||||||
| January 31, | ||||||||
| 2026 | 2025 | |||||||
| Net Sales | ||||||||
| United States | $ | 2,029,021 | $ | 2,139,537 | ||||
| Outside the United States | 7,630 | |||||||
| $ | 2,036,651 | $ | 2,139,537 | |||||
| Property and equipment, not of accumulated depreciation | ||||||||
| United States | $ | 567,255 | $ | 695,063 | ||||
| Outside of the United States | ||||||||
| $ | 567,255 | $ | 695,063 | |||||
| Assets | ||||||||
| Corporate | $ | 4,437,703 | $ | 4,205,577 | ||||
| Pocono Pharmaceuticals | 1,815,731 | 1,404,285 | ||||||
| 4P Therapeutics | 1,294,501 | 1,859,793 | ||||||
| $ | 7,547,935 | $ | 7,469,655 | |||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2026 | Apr 29, 2026 | Showing above |
| 2025 | Apr 28, 2025 | |
| 2024 | May 1, 2024 | |
| 2023 | Apr 26, 2023 | |
| 2022 | Apr 29, 2022 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.